Based on our results, which demonstrate that RAS activation can mediate resistance to ROS1 inhibitors in vitro, we asked whether this pathway might also mediate resistance in ROS1+ NSCLC patients that develop acquired resistance to crizotinib. Here, ROS1 is linked to non-small cell lung carcinoma.